AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2
Open Access
- 1 September 2005
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 12 (3) , 422-430
- https://doi.org/10.1016/j.ymthe.2005.04.019
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Molecular mechanism of psychosine‐induced cell death in human oligodendrocyte cell lineJournal of Neurochemistry, 2003
- Lysosomal storage disorders: Diagnostic dilemmas and prospects for therapyGenetics in Medicine, 2002
- Murine, canine and non-human primate models of Krabbe diseaseMolecular Medicine Today, 2000
- Hematopoietic Stem-Cell Transplantation in Globoid-Cell LeukodystrophyNew England Journal of Medicine, 1998
- Molecular genetics of Krabbe disease (globoid cell leukodystrophy): Diagnostic and clinical implicationsHuman Mutation, 1997
- Molecular Cloning and Expression of cDNA for Murine Galactocerebrosidase and Mutation Analysis of the Twitcher Mouse, a Model of Krabbe's DiseaseJournal of Neurochemistry, 1996
- The Twitcher Mouse: A Model for Krabbe Disease and for Experimental TherapiesBrain Pathology, 1995
- Prolonged Survival and Remyelination After Hematopoietic Cell Transplantation in the Twitcher MouseScience, 1984
- Progressive Accumulation of Toxic Metabolite in a Genetic LeukodystrophyScience, 1984
- Globoid Cell Leucodystrophy (Krabbe's Disease): Deficiency of Galactocerebroside β-GalactosidaseProceedings of the National Academy of Sciences, 1970